ÂÜÀòÂÒÂ×

David Cavalla has a long and varied work experience. David began their career in 1985 as a Principal Research Chemist at Glaxo Group Research. In 1989, they moved to Napp Pharmaceuticals as Head of Biosciences. In 1998, they became CEO of Arachnova Ltd. From 2007 to 2009, they held the roles of CEO for both Myotec Therapeutics Ltd and SwitchPharma Group plc. During this same time period, they also served on the Scientific Advisory Board for Peakdale Molecular Ltd. In 2009, they became the Founder of Numedicus Limited and the Principal of ATPBio. Most recently, they have been the Executive Director of Exvastat since 2016.

David Cavalla completed a Post-doc at the National Institute of Mental Health as a Visiting Fellow in the Laboratory of Preclinical Pharmacology from 1983 to 1985. Prior to that, they obtained a MA and PhD in Synthetic Organic Chemistry from the University of Cambridge between 1976 and 1982.